# US 11,077,137 B2 · Method for treating diastolic heart failure by inhibiting galectin-3

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,137 B2
- Document ID: US11077137B2
- Status: Granted
- Kind: B2
- Application number: 15/877,733
- Filed: 2018-01-23
- Published: 2019-01-03
- Granted: 2021-08-03
- Earliest claimed: 2012-12-20
- Assignees: Henry Ford Health System
- Applicants: Henry Ford Health System
- Inventors: Hani N. Sabbah
- Web page: https://patentgrep.com/patent/US11077137B2

## CPC

- A61K 31/732: Pectin
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating diastolic heart failure is provided including identifying a subject having diastolic heart failure and administering a therapeutically effective amount of a galectin-3 inhibitor to the subject to at least partially alleviate a symptom of diastolic heart failure.

## Claims

### Claim 1

A method for treating heart failure with preserved ejection fraction (HFpEF) in a subject in need thereof, the subject having a left ventricular ejection fraction of greater than 45% before treatment, the method comprising:
administering a therapeutically effective amount of a modified pectin to the subject, the modified pectin having a molecular weight of between about 5 kDa and about 50 kDa.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has a left ventricle of reduced size compared with a control subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has reduced left ventricular end-systolic and end-diastolic volumes compared with a control subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the modified pectin is modified citrus pectin (MCP).

### Claim 5 (depends on 1)

The method of claim 1, wherein administering the modified pectin reduces interstitial fibrosis in the subject compared to before treatment.

### Claim 6 (depends on 1)

The method of claim 1, wherein administering the modified pectin increases left ventricular size in the subject compared to before treatment.

### Claim 7 (depends on 1)

The method of claim 1, wherein administering the modified pectin increases left ventricular end-systolic and end-diastolic volumes in the subject compared to before treatment.

### Claim 8 (depends on 1)

The method of claim 1, wherein administering the modified pectin increases left ventricular ejection fraction in the subject compared to before treatment.

### Claim 9 (depends on 1)

The method of claim 1, wherein administering the modified pectin increases E/A and Ei/Ai ratios in the subject compared to before treatment.

### Claim 10 (depends on 1)

The method of claim 1, wherein the modified pectin has a molecular weight of between about 10 kDa and about 50 kDa.

### Claim 11 (depends on 1)

The method of claim 1, wherein the modified pectin has a molecular weight of between about 5 kDa and about 20 kDa.